share_log

EFFECT: Others

EFFECT: Others

EFFECT:其他
美股SEC公告 ·  2024/12/31 19:05

Moomoo AI 已提取核心信息

Adial Pharmaceuticals, Inc. has received notice from the U.S. Securities and Exchange Commission (SEC) regarding the effectiveness of its Form S-1 registration statement. The effectiveness date is set for December 30, 2024, at 4:00 P.M.The Form S-1, with file number 333-283968, was filed under the company's CIK number 0001513525. This registration statement typically indicates the company's intent to offer securities to the public, which could include an initial public offering (IPO) or a follow-on offering of shares.
Adial Pharmaceuticals, Inc. has received notice from the U.S. Securities and Exchange Commission (SEC) regarding the effectiveness of its Form S-1 registration statement. The effectiveness date is set for December 30, 2024, at 4:00 P.M.The Form S-1, with file number 333-283968, was filed under the company's CIK number 0001513525. This registration statement typically indicates the company's intent to offer securities to the public, which could include an initial public offering (IPO) or a follow-on offering of shares.
Adial Pharmaceuticals, Inc. 已收到美国证券交易委员会(SEC)关于其S-1注册声明有效性的通知。有效日期定于2024年12月30日下午4:00。该S-1表格,文件编号为333-283968,是在公司CIK编号0001513525下提交的。该注册声明通常表示公司意图向公众提供证券,这可能包括首次公开发行(IPO)或后续股份发行。
Adial Pharmaceuticals, Inc. 已收到美国证券交易委员会(SEC)关于其S-1注册声明有效性的通知。有效日期定于2024年12月30日下午4:00。该S-1表格,文件编号为333-283968,是在公司CIK编号0001513525下提交的。该注册声明通常表示公司意图向公众提供证券,这可能包括首次公开发行(IPO)或后续股份发行。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息